title: Selection of cases and controls for the nested case-control study within the Japan Collaborative Cohort Study: the First-wave.
abstract: In this paper, we describe the methodology of the case and control selection for the first-wave nested case-control study within the JACC Study. Among the subjects participating in the cohort, serum samples of 42,249 subjects (including 39,242 subjects aged between 40 and 79 at the baseline) were suitable for biochemical analysis. We here selected those who had died by 1997 or who were diagnosed with cancer with sera until 1994 as cases. For each case, 3 to 4 controls with sera were randomly selected, with matching for gender, age (as near as possible) and residential area. As a result, 3,144 cases and 10,661 controls (2,867 cases and 10,351 controls were 40 to 79 years old at the baseline) were selected to measure serum IGF-I, IGF-II, IGFBP-3, TGF-b1 and sFas values and total SOD activity. Cases were older and more likely to be men than the JACC Study subjects. Moreover, they were much older than controls because of the age-dependence of susceptibility to death, especially among men. There were more smokers among cases compared with controls, though drinkers at the baseline were fewer. Among deceased cases, cancer was the leading cause of death, followed by cardiovascular diseases. Lung cancer was most frequent among deceased cancer cases and the next most common site was the stomach. The leading cause of cancer incidence was stomach cancer followed by lung cancer. Simple comparison of means and distribution of IGF-I, IGF-II, IGFBP-3, TGF-b1, sFas and total SOD activity between cases and controls revealed total SOD activity and sFas levels of cases to be higher than controls, while for the other components the opposite was found.
authors.affiliation: Department of Public Health, Aichi Medical University School of Medicine, Japan. tamaa@aichi-med-u.ac.jp
authors.forename: Akiko
authors.initials: A
authors.lastname: Tamakoshi
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ito
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Inaba
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tajima
authors.forename: Kei
authors.initials: K
authors.lastname: Nakachi
authors.forename: Yohiyuki
authors.initials: Y
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D007564:Japan; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000473:pathology; D018579:Patient Selection; D011379:Prognosis; D013482:Superoxide Dismutase / Q000097:blood; D000072105:Superoxide Dismutase-1; D053773:Transforming Growth Factor beta1 / Q000097:blood; D019014:fas Receptor / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; C491901:FAS protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; C000606290:SOD1 protein, human; C508960:TGFB1 protein, human; D053773:Transforming Growth Factor beta1; D019014:fas Receptor; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1